High inter-observer agreement in immunohistochemical evaluation of HER-2/neu expression in breast cancer: A multicentre GEFPICS study

European Journal of Cancer

Volumn 42, Issue 17, 2006, Pages 2946-2953

  Lacroix Triki, Magali ^a   Mathoulin Pelissier, Simone ^b   Ghnassia, Jean Pierre ^c   Macgrogan, Gaetan ^b   Vincent Salomon, Anne ^d   Brouste, Véronique ^b   Mathieu, Marie Christine ^e   Roger, Pascal ^f   Bibeau, Frédéric ^g   Jacquemier, Jocelyne ^h   Penault Llorca, Frédérique ⁱ   Arnould, Laurent ^j  

^a INSTITUT CLAUDIUS REGAUD   (France)

^b INSTITUT BERGONIÉ   (France)

^c CENTRE PAUL STRAUSS   (France)

^d INSTITUT CURIE   (France)

^e INSTITUT GUSTAVE ROUSSY   (France)

^f MONTPELLIER UNIVERSITY HOSPITAL   (France)

^g CENTRE VAL D AURELLE   (France)

^h Department of Oncological Surgery   (France)

ⁱ CENTRE JEAN PERRIN   (France)

^j CENTRE GEORGES FRANÇOIS LECLERC   (France)

more..

Author keywords

Breast cancer; HER 2 neu; Immunohistochemistry; Inter observer reproducibility; Quality assurance; Ring study

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2;

ADULT; AGED; ARTICLE; BREAST CANCER; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KAPPA STATISTICS; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUALITY CONTROL; REPRODUCIBILITY;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; OBSERVER VARIATION; RECEPTOR, ERBB-2;

EID: 33750530818     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2006.06.020     Document Type: Article

References (28)

1. Slamon D.J., Clark G.M., Wong S.G., et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235 (1987) 177-182
2. Romond E.H., Perez E.A., Bryant J., et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353 (2005) 1673-1684
3. Piccart-Gebhart M.J., Procter M., Leyland-Jones B., et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353 (2005) 1659-1672
4. Di Leo A., Larsimont D., Gancberg D., et al. HER-2 and topo-isomerase II alpha as predictive markers in a population of node-positive breast cancer patients randomly treated with adjuvant CMF or epirubicin plus cyclophosphamide. Ann Oncol 12 (2001) 1081-1089
5. Paik S., Bryant J., Tan-Chiu E., et al. HER2 and choice of adjuvant chemotherapy for invasive breast cancer. National Surgical Adjuvant Breast and Bowel Project Protocol B-15. J Natl Cancer Inst 92 (2000) 1991-1998
6. Penault-Llorca F., Cayre A., Bouchet Mishellany F., et al. Induction chemotherapy for breast carcinoma: predictive markers and relation with outcome. Int J Oncol 22 (2003) 1319-1325
7. Ellis M.J., Coop A., Singh B., et al. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1 and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer. Evidence from a phase III randomized trial. J Clin Oncol 19 (2001) 3808-3816
8. Jacobs T.W., Gown A.M., Yaziji H., et al. Comparison of fluorescence in situ hybridization and immunohistochemistry for the evaluation of HER-2/neu in breast cancer. J Clin Oncol 17 (1999) 1974-1982
9. Jacobs T.W., Gown A.M., Yaziji H., et al. HER-2/neu protein expression in breast cancer evaluated by immunohistochemistry. A study of interlaboratory agreement. Am J Clin Pathol 113 (2000) 251-258
10. Couturier J., Vincent-Salomon A., Nicolas A., et al. Strong correlation between results of fluorescent in situ hybridization and immunohistochemistry for the assessment of the ERBB2 (HER-2/neu) gene status in breast carcinoma. Mod Pathol 13 (2000) 1238-1243
11. Jimenez R.E., Wallis T., Tabasczka P., et al. Determination of HER-2/neu status in breast carcinoma: comparative analysis of immunohistochemistry and fluorescent in situ hybridization. Mod Pathol 13 (2000) 37-45
12. Lebeau A., Deimling D., Kaltz C., et al. HER-2/neu analysis in archival tissue samples of human breast cancer: comparison of immunohistochemistry and fluorescence in situ hybridization. J Clin Oncol 19 (2001) 354-363
13. Kay E.W., Walsh C.J., Cassidy M., et al. C-erbB-2 immunostaining: problems with interpretation. J Clin Pathol 47 (1994) 816-822
14. Cell Markers and Cytogenetics Committees. College of American Pathologists. Clinical laboratory assays for HER-2/neu amplification and overexpression: quality assurance, standardization, and proficiency testing. Arch Pathol Lab Med 126 (2002) 803-808
15. Vincent-Salomon A., MacGrogan G., Couturier J., et al. Calibration of immunohistochemistry for assessment of HER2 in breast cancer: results of the French multicentre GEFPICS study. Histopathology 42 (2003) 337-347
16. Fleiss J.L. Statistical methods for rates and proportions (1981), John Wiley and Sons, New York
17. McGinn T., Wyer P.C., Newman T.B., et al. Tips for learners of evidence-based medicine: 3. Measures of observer variability (kappa statistic). CMAJ 171 (2004) 1369-1373
18. Di Leo A., Dowsett M., Horten B., et al. Current status of HER2 testing. Oncology 63 (2002) 25-32
19. Bilous M., Dowsett M., Hanna W., et al. Current perspectives on HER2 testing: a review of national testing guidelines. Mod Pathol 16 (2003) 173-182
20. Namer M., Gligorov J., Luporsi E., et al. Saint-Paul-de-Vence. 'Cancers du sein' Recommandations pour la pratique clinique. Oncologie 7 (2005) 342-379
21. Roche P.C., Suman V.J., Jenkins R.B., et al. Concordance between local and central laboratory HER2 testing in the breast intergroup trial N9831. J Natl Cancer Inst 94 (2002) 855-857
22. Paik S., Bryant J., Tan-Chiu E., et al. Real-world performance of HER-2 testing - National Surgical Adjuvant Breast and Bowel Project experience. J Natl Cancer Inst 94 (2002) 852-854
23. Tsuda H., Sasano H., Akiyama F., et al. Evaluation of interobserver agreement in scoring immunohistochemical results of HER-2/neu (c-erbB-2) expression detected by HercepTest, Nichirei polyclonal antibody, CB11 and TAB250 in breast carcinoma. Pathol Int 52 (2002) 126-134
24. Santinelli A., Baccarini M., Colanzi P., et al. Immunohistochemical evaluation of HER-2/neu expression in infiltrating breast carcinoma: a study of reproducibility. Anal Quant Cytol Histol 24 (2002) 54-62
25. Hoang M.P., Sahin A.A., Ordonez N.G., et al. HER-2/neu gene amplification compared with HER-2/neu protein overexpression and interobserver reproducibility in invasive breast carcinoma. Am J Clin Pathol 113 (2000) 852-859
26. Thomson T.A., Hayes M.M., Spinelli J.J., et al. HER-2/neu in breast cancer: interobserver variability and performance of immunohistochemistry with 4 antibodies compared with fluorescent in situ hybridization. Mod Pathol 14 (2001) 1079-1086
27. Bilous M., Ades C., Armes J., et al. Predicting the HER-2 status of breast cancer from basic histopathology data: an analysis of 1500 breast cancers as part of the HER2000 International Study. Breast 12 (2003) 92-98
28. Penault-Llorca F., Balaton A., Sabourin J.C., et al. Evaluation immunohistochimique du statut HER-2 dans les carcinomes mammaires infiltrants : mise au point du protocole technique et de la lecture des résultats - recommandations. Ann Pathol 22 (2002) 150-157